London Calling: Long-Term R&D

Key Takeaways

• Scalable flowcells could host up to hundreds of thousands of channels
• Motor proteins aim for 800‑1,000 bases per second, doubling speed
• New pores target higher Q‑scores with lower coverage requirements
• Protein‑sequencing pipeline generated millions of peptide reads per run
• Prototype amino‑acid caller achieved >99% accuracy on phosphorylation detection

Pulse Analysis

Oxford Nanopore’s long‑term vision centers on hardware scalability that could transform laboratory automation. By designing flowcells with hundreds of thousands of nanopores, the company anticipates a shift from boutique sequencers to data‑center‑class instruments that integrate seamlessly into autonomous lab platforms. This scalability, paired with manufacturability and automation, promises lower per‑run costs and the ability to process larger sample batches without sacrificing performance.

Speed and sensitivity are the twin pillars of the upcoming roadmap. Faster motor proteins, projected to reach 800‑1,000 bases per second, would cut turnaround times for critical applications such as infectious‑disease surveillance and real‑time clinical diagnostics. Simultaneously, engineered pores that deliver higher accuracy at reduced coverage could enable reliable variant calling from nanogram‑scale inputs, effectively eliminating the need for amplification in many workflows. For direct RNA, the new motor designs aim to overcome current bottlenecks, delivering orders of magnitude more data from picogram‑level samples.

Perhaps the most disruptive element is the push into peptide and protein sequencing. ONT’s demonstration of millions of peptide reads per PromethION flowcell, combined with an amino‑acid caller that distinguishes phosphorylated from unphosphorylated forms with >99% accuracy, hints at a future where single‑molecule protein analysis rivals mass spectrometry. If the technology matures, researchers could obtain simultaneous genomic, transcriptomic, and proteomic data from the same sample, accelerating biomarker discovery and personalized therapeutics. The absence of concrete timelines suggests these capabilities remain in the prototype stage, but the strategic emphasis underscores Nanopore’s ambition to become a universal, multi‑omics platform.